نتائج البحث - "Emily Sheldon-Waniga"

1

Data from Phase I Study of the Investigational Aurora A Kinase Inhibitor Alisertib plus Rituximab or Rituximab/Vincristine in Relapsed/Refractory Aggressive B-cell Lymphoma

الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::01d62ddf276e9d4e05bedc13051158c0Test
https://doi.org/10.1158/1078-0432.c.6527549.v1Test

2

Figure S2 from Phase I Study of the Investigational Aurora A Kinase Inhibitor Alisertib plus Rituximab or Rituximab/Vincristine in Relapsed/Refractory Aggressive B-cell Lymphoma

الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::35dea50caf664733e0b470fbc480a18fTest
https://doi.org/10.1158/1078-0432.22470386.v1Test

3

Global population pharmacokinetics of the investigational Aurora A kinase inhibitor alisertib in cancer patients: rationale for lower dosage in Asia

المؤلفون: Emily Sheldon-Waniga, Diane R. Mould, Takatoshi Takubo, Xiaofei Zhou, Karthik Venkatakrishnan, Ashley Milton, Dirk Huebner

المصدر: British Journal of Clinical Pharmacology. 84:35-51

الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_________::142b119f38c9e40090be11ebbaa9459eTest
https://doi.org/10.1111/bcp.13430Test

4

Randomized Phase II Study of Paclitaxel plus Alisertib versus Paclitaxel plus Placebo as Second-Line Therapy for SCLC: Primary and Correlative Biomarker Analyses

المصدر: Journal of Thoracic Oncology
r-IIB SANT PAU. Repositorio Institucional de Producción Científica del Instituto de Investigación Biomédica Sant Pau
instname

مصطلحات موضوعية: 0301 basic medicine, Pulmonary and Respiratory Medicine, Oncology, medicine.medical_specialty, Alisertib, Lung Neoplasms, Paclitaxel, Population, Phases of clinical research, Placebo, Disease-Free Survival, 03 medical and health sciences, chemistry.chemical_compound, 0302 clinical medicine, Refractory, Double-Blind Method, Internal medicine, Antineoplastic Combined Chemotherapy Protocols, Clinical endpoint, medicine, small-cell lung cancer, Humans, education, Retrospective Studies, education.field_of_study, business.industry, Hazard ratio, SCLC, Azepines, Phase II, 030104 developmental biology, Pyrimidines, Treatment Outcome, chemistry, 030220 oncology & carcinogenesis, Aurora A kinase, Neoplasm Recurrence, Local, business, Biomarkers

وصف الملف: Print-Electronic

الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a96c0e2d242d5e686470324fde43d32bTest
https://pubmed.ncbi.nlm.nih.gov/31655296Test

5

Alisertib in Combination With Weekly Paclitaxel in Patients With Advanced Breast Cancer or Recurrent Ovarian Cancer: A Randomized Clinical Trial

مصطلحات موضوعية: Adult, Oncology, Cancer Research, medicine.medical_specialty, Time Factors, Paclitaxel, Population, Phases of clinical research, Breast Neoplasms, 03 medical and health sciences, chemistry.chemical_compound, 0302 clinical medicine, Internal medicine, Antineoplastic Combined Chemotherapy Protocols, Clinical endpoint, Humans, Medicine, 030212 general & internal medicine, Progression-free survival, education, Aged, Neoplasm Staging, Original Investigation, Aged, 80 and over, Ovarian Neoplasms, education.field_of_study, Intention-to-treat analysis, Taxane, business.industry, Azepines, Middle Aged, Progression-Free Survival, United States, Europe, Pyrimidines, chemistry, 030220 oncology & carcinogenesis, Alisertib, Disease Progression, Female, Neoplasm Recurrence, Local, business

الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::9638646354a6502b409da939af67720eTest
https://europepmc.org/articles/PMC6439781Test/

6

Phase I Study of the Investigational Aurora A Kinase Inhibitor Alisertib plus Rituximab or Rituximab/Vincristine in Relapsed/Refractory Aggressive B-cell Lymphoma

المصدر: Clin Cancer Res

مصطلحات موضوعية: 0301 basic medicine, Oncology, Male, Cancer Research, chemistry.chemical_compound, 0302 clinical medicine, immune system diseases, Recurrence, hemic and lymphatic diseases, Antineoplastic Combined Chemotherapy Protocols, Medicine, Molecular Targeted Therapy, Neoplasm Metastasis, B-cell lymphoma, Aurora Kinase A, Aged, 80 and over, Azepines, Middle Aged, Treatment Outcome, Vincristine, 030220 oncology & carcinogenesis, Retreatment, Disease Progression, Rituximab, Female, Drug Monitoring, medicine.drug, Adult, medicine.medical_specialty, Lymphoma, B-Cell, Maximum Tolerated Dose, Aurora A kinase, Neutropenia, Article, 03 medical and health sciences, Refractory, Internal medicine, Humans, Aged, Neoplasm Staging, business.industry, medicine.disease, Lymphoma, 030104 developmental biology, Pyrimidines, chemistry, Drug Resistance, Neoplasm, Alisertib, business

الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::07b7c08ea73c1a23e1be920e804e80a6Test
https://europepmc.org/articles/PMC7731903Test/

7

TAK-659, AN INVESTIGATIONAL REVERSIBLE DUAL SYK/FLT-3 INHIBITOR, IN PATIENTS WITH LYMPHOMA: UPDATED RESULTS FROM DOSE-ESCALATION AND EXPANSION COHORTS OF a PHASE 1 STUDY

المصدر: Hematological Oncology. 35:72-74

مصطلحات موضوعية: Oncology, Cancer Research, medicine.medical_specialty, business.industry, Syk, Hematology, General Medicine, Pharmacology, medicine.disease, Lymphoma, 03 medical and health sciences, 0302 clinical medicine, 030220 oncology & carcinogenesis, Internal medicine, medicine, Dose escalation, In patient, business, 030215 immunology

الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_________::4706be646ef6dd31c449158b7bb4413fTest
https://doi.org/10.1002/hon.2437_60Test

8

OA05.05 Randomized Phase 2 Study: Alisertib (MLN8237) or Placebo + Paclitaxel as Second-Line Therapy for Small-Cell Lung Cancer (SCLC)

المؤلفون: Dirk Huebner, Claudio Dansky Ullmann, Kristiaan Nackaerts, E. Jane Leonard, David R. Spigel, Gyula Ostoros, Erin Zagadailov, Taofeek K. Owonikoko, Emily Sheldon-Waniga, Christina S. Baik, Tibor Csoszi

المصدر: Journal of Thoracic Oncology. 12:S261-S262

الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_________::64fd5884621cedb4dbe1dee27ed61620Test
https://doi.org/10.1016/j.jtho.2016.11.253Test

9

First-in-human phase 1 study of TAK-931, an oral cell division cycle 7 (CDC7) inhibitor, in patients (pts) with advanced solid tumors

المؤلفون: Shunsuke Kondo, Yasutoshi Kuboki, Hongmei Li, Xiaofei Zhou, Emily Sheldon-Waniga, Toshihiko Doi, Noboru Yamamoto, Toshio Shimizu, Brittany Bahamon, Hideaki Takahashi

المصدر: Journal of Clinical Oncology. 36:2506-2506

مصطلحات موضوعية: 0301 basic medicine, Antitumor activity, Cancer Research, business.industry, Kinase, DNA damage, DNA replication, A protein, First in human, Cell division cycle, 03 medical and health sciences, 030104 developmental biology, Oncology, Cancer research, Medicine, In patient, business

الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_________::f3ae6b92fce52fd6aa046413ff3523b8Test
https://doi.org/10.1200/jco.2018.36.15_suppl.2506Test

10

Updated Results from a Phase 1 Study of TAK-659, an Investigational and Reversible SYK Inhibitor, in Patients (Pts) with Advanced Solid Tumor or Lymphoma Malignancies

المصدر: Blood. 128:624-624

الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_________::925f15ba45e782457b272f01b06d8f22Test
https://doi.org/10.1182/blood.v128.22.624.624Test

تنقيح النتائج